Glucose modulates growth of gingival fibroblasts and periodontal ligament cells: correlation with expression of basic fibroblast growth factor.
Diabetes mellitus is a systemic disease with profound effects on oral health and periodontal wound healing. Uncontrolled diabetes adversely affects surgical wound healing and is often associated with abnormal proliferation of fibroblasts, excessive angiogenesis and poor bone regeneration. Human gingival fibroblasts and periodontal ligament cells from both diabetics and non-diabetics were evaluated for growth responses following culture in 20 mM glucose, a concentration compatible with blood glucose levels in uncontrolled diabetics. Gingival fibroblasts derived from 9 non-diabetic patients and 3 insulin-dependent diabetics either proliferated or showed little change of growth in elevated glucose. Enhanced proliferation was observed following 1 wk of culture in glucose. Growth of periodontal ligament cells from 5 non-diabetic patients was inhibited by 20 mM glucose. Fibroblasts that were markedly growth stimulated were probed for expression of basic fibroblast growth factor (bFGF) using a reverse-transcribed polymerase chain reaction (RT-PCR). Results indicate that fibroblasts exhibiting the greatest increase in growth in response to high glucose also exhibited increased expression of bFGF. No changes were observed in mRNA expression for platelet-derived growth factor-AA, platelet-derived growth factor-BB, insulin-like growth factor and transforming growth factor-beta 1. Mitogenic effects induced by the cytosol of fibroblasts exhibiting increases of growth in 20 mM glucose were abrogated by neutralizing antibodies to bFGF. In addition, some periodontal ligament cells that were growth inhibited by high glucose had reduced expression of bFGF. These data suggest that bFGF may play a role in the abnormal wound healing associated with periodontal surgery of uncontrolled diabetics.
Ohgi
S
S
Department of Stomatology, School of Dentistry, University of California, San Francisco 94143-0650, USA.
Johnson
P W
PW
D000906:Antibodies; D000077214:Becaplermin; D001861:Bone Regeneration; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003470:Culture Media; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism / Q000473:pathology; D016222:Fibroblast Growth Factor 2 / Q000187:drug effects / Q000235:genetics* / Q000276:immunology; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects*; D005786:Gene Expression Regulation / Q000187:drug effects; D005881:Gingiva / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development; D005947:Glucose / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000187:drug effects / Q000235:genetics; D008934:Mitogens; D009389:Neovascularization, Pathologic; D010513:Periodontal Ligament / Q000166:cytology / Q000187:drug effects*; D010982:Platelet-Derived Growth Factor / Q000187:drug effects / Q000235:genetics; D016133:Polymerase Chain Reaction; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics; D014158:Transcription, Genetic; D016212:Transforming Growth Factor beta / Q000187:drug effects / Q000235:genetics; D014945:Wound Healing
D000906:Antibodies; D003470:Culture Media; D008934:Mitogens; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; C075278:platelet-derived growth factor A; D016222:Fibroblast Growth Factor 2; D000077214:Becaplermin; D007334:Insulin-Like Growth Factor I; D005947:Glucose